Cemiplimab plus gemcitabine for metastatic pancreatic cancer
Part of Cancer clinical trials.
This trial tests a combination of an immunotherapy drug (cemiplimab) and chemotherapy (gemcitabine) for people with pancreatic cancer that has spread to other parts of the body. It is for those whose tumors have specific genetic changes (in the SWI/SNF genes) and have only had one prior treatment that was not immunotherapy.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 or older.
- Your pancreatic cancer must have spread to other parts of your body (stage IV).
- Your tumor must have certain genetic changes (in the SWI/SNF genes) found by a special lab test.
- You can have had only one prior treatment for your pancreatic cancer, and that treatment must not have been immunotherapy.
- You must be in fairly good health (able to care for yourself) and have adequate blood, liver, and kidney function.
- You cannot have certain health conditions like an autoimmune disease, organ transplant, or active hepatitis B or C.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new targeted drug (LM-302) combined with a standard chemotherapy drug (gemcitabine) for people with advanced pancreatic cancer that has progressed after initial treatment. The goal is to see if this combination can slow down or shrink the cancer.
This trial tests a new immunotherapy drug called ivonescimab combined with chemotherapy, with or without another experimental drug (AK117), for people with pancreatic cancer that has spread. The goal is to see if adding these therapies can help shrink tumors or slow the cancer's growth.
This study tests a new immunotherapy drug (cemiplimab) combined with chemotherapy for advanced squamous lung cancer. The treatment is chosen based on a blood test that measures a natural body enzyme, which may help predict how well the chemotherapy works.
This trial tests whether adding the immunotherapy drug cemiplimab to standard treatment can help people with advanced lung cancer that has already progressed after both platinum chemo and a prior immunotherapy. It is designed for those who responded to their first immunotherapy for at least 12 weeks before the cancer started growing again.
This trial tests a combination of a targeted immune therapy (Adebrelimab) with three chemotherapy drugs for people with metastatic pancreatic cancer who haven't had any treatment yet. The goal is to see if this combination can shrink tumors and help people live longer.
This trial tests a drug called cemiplimab (an immunotherapy) for people with advanced lung cancer that has high PD-L1 levels. It uses a simple blood test to track how well the treatment is working.
Hear when a new Pancreatic Ductal Adenocarcinoma (mPDAC) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.